REPLIGEN CORP Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
REPLIGEN CORP (RGEN) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $928.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2017-02-23
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2016-12-31 was $0.00.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2016-09-30 was $0.00.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2014-12-31 was $0.00.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2014-09-30 was -$30.00K.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2016 was $928.00K.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2014 was $1.37M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $0.00 derived: sum of 2 quarters · filed 2017-02-23 | $928.00K 10-K · filed 2017-02-23 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $928.00K 10-Q · filed 2016-11-03 | ||
| 2016-06-30 | $928.00K 10-Q · filed 2016-08-04 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-17 | -$30.00K derived: sum of 2 quarters · filed 2015-03-17 | $1.37M 10-K · filed 2015-03-17 | |
| 2014-09-30 | -$30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $1.37M 10-Q · filed 2014-11-07 | ||
| 2014-06-30 | $1.40M 10-Q · filed 2014-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |